Literature DB >> 27123908

AMCP Format for Formulary Submissions, Version 4.0.

Alan Pannier1, Jeffrey D Dunn2.   

Abstract

DISCLOSURES: Pannier is a member of the AMCP Format Executive Committee. The authors report no financial or other conflicts of interest related to the subject of this letter.

Entities:  

Mesh：

Year:  2016        PMID： 27123908     DOI： 10.18553/jmcp.2016.16092

Source DB:  PubMed          Journal:  J Manag Care Spec Pharm


  5 in total

1.  Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US.

Authors:  Murtuza Bharmal; Mairead Kearney; Ying Zheng; Hemant Phatak
Journal:  Clinicoecon Outcomes Res       Date:  2019-05-22

2.  The CHIRPY DRAGON intervention in preventing obesity in Chinese primary-school--aged children: A cluster-randomised controlled trial.

Authors:  Bai Li; Miranda Pallan; Wei Jia Liu; Karla Hemming; Emma Frew; Rong Lin; Wei Liu; James Martin; Mandana Zanganeh; Kiya Hurley; Kar Keung Cheng; Peymane Adab
Journal:  PLoS Med       Date:  2019-11-26       Impact factor: 11.069

3.  Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives.

Authors:  Thitima Kongnakorn; Murtuza Bharmal; Mairead Kearney; Hemant Phatak; Agnes Benedict; Abhijeet Bhanegaonkar; Matthew Galsky
Journal:  Clinicoecon Outcomes Res       Date:  2019-11-08

4.  Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.

Authors:  Tereza Lanitis; Irina Proskorovsky; Apoorva Ambavane; Matthias Hunger; Ying Zheng; Murtuza Bharmal; Hemant Phatak
Journal:  Adv Ther       Date:  2019-07-26       Impact factor: 3.845

5.  Influence of Hospital Formularies on Outpatient Prescribing Practices: Analysis of the Introduction of a Local Formulary: A Single-Center, 2-Year Follow-Up, Retrospective Cohort Study of a Local Formulary in Japan.

Authors:  Norihito Kanai; Masazumi Ando; Momoko Shimodate; Yoshiko Miyazaki; Toshio Saito
Journal:  Inquiry       Date:  2022 Jan-Dec       Impact factor: 1.730
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.